alirocumab vs ezetimibe/simvastatin
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of alirocumab and ezetimibe/simvastatin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Praluent
Vytorin
Praluent is a medicine that can lower cholesterol. It can also lower the risk of heart problems like heart attack or stroke in some adults.
Vytorin is a combination medicine that contains ezetimibe and simvastatin. It helps lower bad cholesterol (LDL-C) in your blood.
Praluent is used to lower LDL cholesterol (bad cholesterol). It is used along with diet and exercise in adults with high cholesterol. It is also used in adults and children 8 years and older who have a genetic condition that causes high cholesterol.
Vytorin is used along with a healthy diet to lower high LDL cholesterol. It is used in adults with primary hyperlipidemia and in adults and children 10 years and older with heterozygous familial hypercholesterolemia (HeFH). Vytorin can also be used with other cholesterol-lowering treatments for adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin, one of the drugs in Vytorin, can also lower the risk of heart problems like heart attack and stroke in adults with heart disease, blood vessel disease, or diabetes.
Praluent is a PCSK9 inhibitor. It works by blocking a protein in your body called PCSK9. Blocking this protein helps your body remove LDL cholesterol from your blood.
Ezetimibe reduces the amount of cholesterol your body absorbs from food. Simvastatin belongs to a class of drugs called statins. Statins lower cholesterol by blocking a substance your body needs to make cholesterol.
- • Injection site reactions (redness, itching, swelling, pain)
- • Flu
- • Muscle pain
- • Diarrhea
- • Headache
- • Increased liver enzyme (ALT)
- • Muscle pain
- • Upper respiratory tract infection
- • Diarrhea
- Myalgia 1,655
- Product Dose Omission 1,364
- Injection Site Pain 1,278
- Muscle Spasms 1,162
- Arthralgia 1,053
- Feeling sick to your stomach 1,008
- Feeling tired 771
- Feeling lightheaded 731
- General pain 702
- Muscle pain 669
Serious allergic reactions have happened with Praluent, sometimes requiring hospitalization. If you have signs of a serious allergic reaction, stop using Praluent and get medical help right away.
Vytorin can cause muscle problems, including myopathy and rhabdomyolysis. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness, especially if you also have a fever or feel sick. Vytorin can also cause liver problems. Your doctor may do blood tests to check your liver before you start taking Vytorin and while you take it.
There is not enough information about Praluent use during pregnancy to know if it is safe. If you are pregnant or plan to become pregnant, talk to your doctor before using Praluent.
Do not take Vytorin if you are pregnant. It can harm your unborn baby. Talk to your doctor if you are breastfeeding or plan to breastfeed, as it is not recommended during treatment with Vytorin.
Also Compare, Nearby Drugs
Compare alirocumab with
How to Read This alirocumab vs ezetimibe/simvastatin Comparison
alirocumab is classified in the PCSK9 Inhibitor drug class, while ezetimibe/simvastatin sits within the Cholesterol Absorption Inhibitor / Statin Combination class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, alirocumab has 6,512 submissions while ezetimibe/simvastatin has 3,881. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for alirocumab or ezetimibe/simvastatin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.